SCHEMBL3322341

SCHEMBL3322341

CC1(C)CCC[C@@]2(C)[C@H]1CCC1(C)OC(=O)C[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
CYP2C19 P33261 1/20 1.00
ENTPD5 O75356 1/20 0.54
RPS6KA5 O75582 3/20 0.46
MAPKAPK2 P49137 3/20 0.46
LTB4R Q15722 1/20 0.46
ALOX15 P16050 2/20 0.44
ALOX12 P18054 2/20 0.44
NR1H4 Q96RI1 3/20 0.40
PTPN1 P18031 4/20 0.40
HIF1A Q16665 3/20 0.40
EPAS1 Q99814 3/20 0.40
IDO1 P14902 1/20 0.39
PIK3CB P42338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17030368 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL9289576 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL6251885 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL12794189 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL1096342 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL9572259 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL13206588 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL18256420 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL83395 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19
SCHEMBL13223919 1.00 ALDH1A1 (1.00) ALDH1A1CYP3A4CYP2C9TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023215619-A2 ANTIMICROBIAL COMPOSITIONS AND USES FOR TREATMENT OF CLOSTRIDIOIDES DIFFICILE, MYCOBACTERIUM TUBERCULOSIS, AND ENTEROCOCCUS FAECALIS INFECTION UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2023-11-09 WO disclosed
EP-1868964-B1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH & CIE (CH) 2016-11-23 EP disclosed
US-20100280273-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA (CH) 2010-11-04 US disclosed
US-7763758-B2 Complex containing amino or imino groups with phosphino group FIRMENICH SA (CH) 2010-07-27 US disclosed
US-20100130754-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES FIRMENICH SA 2010-05-27 US disclosed
US-20080071121-A1 Complex containing amino or imino groups with phosphino group FIRMENICH SA (CH) 2008-03-20 US disclosed
EP-0472123-B1 Propellanes GIVAUDAN ROURE INT (CH) 1994-05-04 EP disclosed
EP-0472123-A1 Propellanes GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) 1992-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130754-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES ADH5, ADH1A, ADH1C ALDH1A1 1267/4885CYP3A4 107/4885CYP2C9 1104/4885
US-20080071121-A1 Complex containing amino or imino groups with phosphino group ADH1C, ADH5, PHOSPHO1 ALDH1A1 1786/4885CYP3A4 1397/4885CYP2C9 1974/4885
US-20100280273-A1 HYDROGENATION OF ESTERS WITH RU/BIDENTATE LIGANDS COMPLEXES ADH5, ADH1A, ADH1C ALDH1A1 1267/4885CYP3A4 107/4885CYP2C9 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.